Shire plc (LSE: SHP, NASDAQ: SHPG) has announced the acquisition of Foresight Biotechnologies Inc., based in New York for $300 million in an all-cash deal.… Read More »Shire Pharmaceuticals acquires Foresight Biotherapeutics Inc. to gain infectious conjunctivitis treatment entering Phase III
Applied Genetic Technologies Corp. (NASDAQ: AGTC) and Biogen Inc. (NASDAQ: BIIB) have announced a collaborative partnership to develop gene therapies for ophthalmic disease. According to… Read More »Applied Genetic Technologies Corp. (NASDAQ:AGTC) and Biogen Inc. (NASDAQ:BIIB) sign commercial agreement to develop gene therapies for ophthalmic disease
Shire plc (LSE: SHP, NASDAQ: SHPG) and the US Foundation Fighting Blindness (FFB) are set to collaborate on a new initiative to accelerate the development… Read More »Shire plc sign research agreement with Foundation Fighting Blindness on development of treatments for autosomal dominant retinitis pigmentosa
Bayer HealthCare (Bayer AG, Xetra: BAYN, Leverkusen, Germany) and the Johns Hopkins University in Baltimore, Maryland, USA, have announced the establishment of a formal collaborative… Read More »Bayer HealthCare and Johns Hopkins University sign five (5)-year collaboration agreement to develop retinal disease treatments
Spark Therapeutics, Inc. (NASDAQ: ONCE) and Clearside Biomedical, Inc. (Alpharetta, Georgia, USA) have announced the execution of an option agreement to facilitate a potential acquisition… Read More »Spark Therapeutics (NYSE: ONCE) executes option deal with Clearside Biomedical for ocular micro-injector technology.
Actavis plc (NYSE: ACT) has announced receipt of communication from the UK National Institute for Health and Care Excellence (NICE) indicating support for the use… Read More »Actavis plc (NYSE: ACT) announces UK NICE proposal for Ozurdex (dexamethasone 0.7mg) as a treatment for certain diabetic macular edema (DME) patients.
A relatively new company, Eyenuk Inc., based in Los Angeles, California, has announced the receipt of CE approval for a new diabetic retinopathy (DR) screening… Read More »Eyenuk Inc., announces CE approval for new diabetic retinopathy screening tool
Ocata Therapeutics Inc., (formerly Advanced Cell Technology), a regenerative cell therapy company focused on ophthalmic disorders, has announced the execution of a licensing deal for… Read More »Ocata Therapeutics licenses induced pluripotent stem cell (iPSC) technology from Allele Biotechnology Inc.
Ophthotech Corporation (Nasdaq: OPHT) has announced that it has reached a second $50 million milestone payment from Novartis Pharma AG as part of an ex-US… Read More »Ophthotech Corporation receives $50M milestone payment from Novartis for development of Fovista
A new report produced by a business and market research company (Vertical Edge Limited, London, UK) has predicted that sales of Regeneron’s Eylea (aflibercept) will… Read More »Eylea is forecast to attain revenues of US$4,475 million and overtake Lucentis revenues by 2022